Manufacturer
XEPA-SOUL PATTINSON (MALAYSIA) SDN BHD
Contents
ROSUVASTATIN CALCIUM
Indication
Reduction of elevated total cholesterol (total-C), LDL-C, ApoB, total-C: HDL-C ratio, triglycerides & increasing HDL-C in hyperlipidemic & dyslipidemic conditions. Reduction of total mortality & risk of major CV events (CV death, stroke, MI, unstable angina or arterial revascularization) in adults w/ increased risk of atherosclerotic CV disease based on the presence of CV disease risk markers. Primary dysbetalipoproteinemia (type III hyperlipoproteinemia); primary hypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia & severe non-familial hypercholesterolaemia); combined (mixed) dyslipidemia (type IIb); homozygous familial hypercholesterolaemia. Adjunctive therapy to diet to slow the progression of atherosclerosis in adults as part of treatment strategy to lower total-C & LDL-C to target levels. Adjunct to diet to reduce total-C, LDL-C & ApoB levels in adolescents who are at least 1 yr post-menarche, 10-17 yr w/ heterozygous familial hypercholesterolemia.
Instruction
May be taken with or without food.
Drug interaction
Increased plasma conc w/ transporter protein inhibitors. Increased exposure w/ PIs. Increased Cmax & AUC w/ gemfibrozil. Increased AUC w/ ezetimibe. Decreased plasma conc w/ antacid. Decreased AUC & Cmax w/ erythromycin. Increased INR w/ vit K antagonists. Increased ethinylestradiol & norgestrel AUC. Severe myositis & myoglobinuria w/ fibrates. Muscle-related events w/ fusidic acid.
Malaysia
